

IFN-alpha 4 Protein, Cynomolgus (HEK293, Fc)

Cat. No.:	HY-P77391
Synonyms:	Interferon alpha-4; IFN-alpha-4; INFA4
Species:	Cynomolgus
Source:	HEK293
Accession:	NP_001181313 (C24-N189)
Gene ID:	710654
Molecular Weight:	Approximately 48 kDa

PROPERTIES

AA Sequence	<p> CDLPQTHSLG NRRALILLAQ MGRISPFSC L KDRHDFGFPQ EEFDGNQFQT AQAMSVLHEM IQQTFNLFST KDS SAAWEQN LLEKFSTELY QQLSDLEACV IQEAGVGETP LMNEDSILAV RKYFQRITLY LMEKKYSPCA WEVVRAEIMR SLSFSTNLQK RL R K K N </p>
Appearance	Lyophilized powder.
Formulation	Lyophilized from a 0.2 µm filtered solution of PBS, pH 7.4.
Endotoxin Level	<1 EU/µg, determined by LAL method.
Reconstitution	It is not recommended to reconstitute to a concentration less than 100 µg/mL in ddH ₂ O. For long term storage it is recommended to add a carrier protein (0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose).
Storage & Stability	Stored at -20°C for 2 years. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.
Shipping	Room temperature in continental US; may vary elsewhere.

DESCRIPTION

Background	<p>IFN-alpha 4 (IFNA4; IFN-α4), belongs to the alpha/beta interferon (IFN) family, is produced by the macrophages with antiviral activities. Interferon (IFN) is originally identified as a substance 'interfering' with viral replication in vitro. IFN-α/β and related molecules are classified as type I IFNs, as for the other two types of type II IFN (IFN-γ) and type III IFNs (IFN-λ), respectively^[1].</p> <p>Interferon alpha (IFNa) shows significant biological activity in various cancers, particularly haematological malignancies such as hairy cell leukaemia and chronic myelogenous leukaemia^[2].</p> <p>IFN-alpha 4 is the subtypes dominates in IFN-alpha, whose the response with IFNA5, IFNA7, and IFNA14 accounting for up to</p>
------------	---

85% of the subtypes expressed by Peripheral blood mononuclear cells (PBMCs)^[3].
IFN-alpha 4 is promoted by interferon (IFN) regulatory factors (IRFs), especially IRF-1 and IRF-7^{[5][6]}. And it exhibits function by inhibiting virus RNA replication and enhances human natural killer cytotoxicity against virus^{[4][7]}.

REFERENCES

- [1]. Zhang SY, et al. Inborn errors of interferon (IFN)-mediated immunity in humans: insights into the respective roles of IFN-alpha/beta, IFN-gamma, and IFN-lambda in host defense. *Immunol Rev.* 2008 Dec;226:29-40.
- [2]. Raj NB, et al. Identification of a novel virus-responsive sequence in the promoter of murine interferon-alpha genes. *J Biol Chem.* 1991 Jun 15;266(17):11360-5.
- [3]. Li Y, et al. Expression Pattern of Individual IFNA Subtypes in Chronic HIV Infection. *J Interferon Cytokine Res.* 2017 Dec;37(12):541-549.
- [4]. Verhagen A, et al. Comparison of augmentation of human natural killer cell cytotoxicity by interferon-alpha subtypes. *Nat Immun Cell Growth Regul.* 1990;9(5):325-33.
- [5]. Au WC, et al. Identification of a member of the interferon regulatory factor family that binds to the interferon-stimulated response element and activates expression of interferon-induced genes. *Proc Natl Acad Sci U S A.* 1995 Dec 5;92(25):11657-61.
- [6]. Lin R, et al. Selective DNA binding and association with the CREB binding protein coactivator contribute to differential activation of alpha/beta interferon genes by interferon regulatory factors 3 and 7. *Mol Cell Biol.* 2000 Sep;20(17):6342-53.
-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA